Bacteriophage therapy – Still promising but not delivering
post-template-default,single,single-post,postid-7761,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Dr David Harper presents “Bacteriophage therapy – Still promising but not (yet) delivering” at Euroscicon

Bedford, UK, and Austin, Texas; November 10th 2016
Evolution Biotechnologies (, the company working to expand the use of biological control into medically important areas, today announces a presentation by its Chief Officer, Dr. David Harper.
The presentation, entitled “Bacteriophage therapy – Still promising but not (yet) delivering” is to be given on Thursday 10th November via webex at the virtual conference held by Euroscicon on Developing antibiotic alternatives: A discussion of new approaches to overcoming antimicrobial resistance.

About Evolution Biotechnologies
Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work is based on developing biological controls for of the house dust mite, with the company now expanding into phage therapy, a highly promising approach to controlling antimicrobial resistance. The development of additional technologies is planned for the future.

About biological control
Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

No Comments

Sorry, the comment form is closed at this time.